Skip to main content

X4 Pharmaceuticals, Inc

XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001501697

In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 3 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding X4 Pharmaceuticals, Inc changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of XFOR: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders5242−10
Shares2.80M16.2M+13.4M (+476.2%)
Value$5.33M$55.3M+$49.9M (+937.2%)

New holders (11)

Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to XFOR in Q3 2025
InstitutionSharesValue% of portfolio
BVF Inc2,233,742$7.64M0.31%
Nantahala Capital Management, LLC2,228,350$7.62M0.47%
Rosalind Advisors, Inc.1,544,607$5.28M1.92%
Deep Track Capital, LP1,122,484$3.84M0.11%
Stonepine Capital Management, LLC1,056,338$3.61M2.94%
StemPoint Capital LP555,411$1.90M0.38%
Boothbay Fund Management, LLC343,963$1.18M0.03%
Palumbo Wealth Management LLC95,327$326.0K0.10%
Two Sigma Investments, LP13,868$47.4K0.00%
Point72 Asia (Singapore) Pte. Ltd.2,914$9.97K0.00%
Rockefeller Capital Management L.P.33$1130.00%

Sold out (21)

Institutions that held X4 Pharmaceuticals, Inc at the end of Q2 2025 and filed for Q3 2025 without it.